Endpoints News. by John Carroll
April 28, 2017 07:38 AM
¨5. Actimmune $572,292¨
Company: Horizon
Category: Rare disease – orphan drug
(Interferon gamma 1-b)
Approved for severe, malignant osteopetrosis and chronic granulomatous disease, rare genetic diseases, Actimmune noted last last year that the drug failed a Phase III for Friedreich’s ataxia. Horizon obtained a separate orphan drug designation for the drug when it decided to mount the study.
Monday, May 1, 2017
Subscribe to:
Posts (Atom)
